@bedger and @@truss20 agree with your assertion of the potential value here. I am thinking that people maybe hesitant to jump in now with a cap raise before or at the time of GVHD readout likely (in my view) to maintain at least 6 months of cash runway. Having said that, the exercising of options if the price goes above 30c by 1st April could generate $5m in cash for the company which will extend the cash runway so that a cap raise becomes less likely by end of this year. I am not holding my breadth but will be ready to place a sizable order in this scenario. I was lucky to obtain 250K shares at just below 19cents which I am retaining predominately in case of a partnership/acquisition event. Hoping for a different result to my incurred loses on this share a few years back with the anticipated $2 buy-out did not go ahead. The recent rise of MSB and OCC have been remarkable and I continue to add on weakness in both shares with a strong conviction towards the becoming stem-cell industry, and Australian leadership in this space. Good luck everyone. VFM
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)